0 0 Probus Medicines Limited 13529719 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is as a dispensing chemist. Digita Accounts Production Advanced 6.30.9574.0 true true 13529719 2024-04-01 2025-03-31 13529719 2025-03-31 13529719 bus:OrdinaryShareClass1 2025-03-31 13529719 core:RetainedEarningsAccumulatedLosses 2025-03-31 13529719 core:ShareCapital 2025-03-31 13529719 core:CurrentFinancialInstruments 2025-03-31 13529719 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 13529719 core:PatentsTrademarksLicencesConcessionsSimilar 2025-03-31 13529719 core:FurnitureFittings 2025-03-31 13529719 bus:SmallEntities 2024-04-01 2025-03-31 13529719 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 13529719 bus:FilletedAccounts 2024-04-01 2025-03-31 13529719 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 13529719 bus:RegisteredOffice 2024-04-01 2025-03-31 13529719 bus:Director1 2024-04-01 2025-03-31 13529719 bus:Director2 2024-04-01 2025-03-31 13529719 bus:Director3 2024-04-01 2025-03-31 13529719 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 13529719 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 13529719 core:ComputerSoftware 2024-04-01 2025-03-31 13529719 core:PatentsTrademarksLicencesConcessionsSimilar 2024-04-01 2025-03-31 13529719 core:FurnitureFittings 2024-04-01 2025-03-31 13529719 core:PlantMachinery 2024-04-01 2025-03-31 13529719 1 2024-04-01 2025-03-31 13529719 countries:England 2024-04-01 2025-03-31 13529719 2024-03-31 13529719 core:PatentsTrademarksLicencesConcessionsSimilar 2024-03-31 13529719 core:FurnitureFittings 2024-03-31 13529719 2023-04-01 2024-03-31 13529719 2024-03-31 13529719 bus:OrdinaryShareClass1 2024-03-31 13529719 core:RetainedEarningsAccumulatedLosses 2024-03-31 13529719 core:ShareCapital 2024-03-31 13529719 core:CurrentFinancialInstruments 2024-03-31 13529719 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 13529719 core:PatentsTrademarksLicencesConcessionsSimilar 2024-03-31 13529719 core:FurnitureFittings 2024-03-31 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 13529719

Probus Medicines Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2025

 

Probus Medicines Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 9

 

Probus Medicines Limited

Company Information

Directors

Mr J S Casey

Dr R Murthy

Dr K Smithson

Registered office

The Surgery
Tregony Road
Probus
Cornwall
TR2 4JZ

 

Probus Medicines Limited

(Registration number: 13529719)
Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Intangible assets

4

1,344

2,334

Tangible assets

5

6,261

3,830

 

7,605

6,164

Current assets

 

Debtors

6

100

100

Creditors: Amounts falling due within one year

7

(22,703)

(15,585)

Net current liabilities

 

(22,603)

(15,485)

Total assets less current liabilities

 

(14,998)

(9,321)

Provisions for liabilities

(1,901)

(1,275)

Net liabilities

 

(16,899)

(10,596)

Capital and reserves

 

Called up share capital

8

100

100

Retained earnings

(16,999)

(10,696)

Shareholders' deficit

 

(16,899)

(10,596)

 

Probus Medicines Limited

(Registration number: 13529719)
Balance Sheet as at 31 March 2025

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 2 August 2025 and signed on its behalf by:
 

.........................................
Mr J S Casey
Director

 

Probus Medicines Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
The Surgery
Tregony Road
Probus
Cornwall
TR2 4JZ

These financial statements were authorised for issue by the Board on 2 August 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Disclosure of long or short period

The comparative period is for the 9 months from 1 July 2023 to 31 March 2024.

 

Probus Medicines Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Going concern

The financial statements have been prepared on a going concern basis.

The directors acknowledge the company's net current and net liability position at the balance sheet date and the result for the year ended 31 March 2025. This position is expected given that the company was preparing to become operational during the year and only started trading after the year end date on 1 April 2025.

Included within creditors: amounts due within one year is £21,541 (2024: £14,685) which is owed to the parent company and a related entity. The parent company and related entity have provided assurances that this debt will not be called in until the company is in a position to afford the repayment.

On the basis of these assurances, the directors have satisfied themselves that the company is a going concern and have prepared the accounts on this basis.

Tax

Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Furniture, fittings and equipment

5 years straight line

 

Probus Medicines Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Intangible assets

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Software

3 years straight line

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 0 (2024 - 0).

 

Probus Medicines Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

4

Intangible assets

Software
 £

Total
£

Cost or valuation

At 1 April 2024

3,000

3,000

At 31 March 2025

3,000

3,000

Amortisation

At 1 April 2024

666

666

Amortisation charge

990

990

At 31 March 2025

1,656

1,656

Carrying amount

At 31 March 2025

1,344

1,344

At 31 March 2024

2,334

2,334

 

Probus Medicines Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

5

Tangible assets

Furniture, fittings and equipment
£

Total
£

Cost or valuation

At 1 April 2024

4,183

4,183

Additions

4,085

4,085

At 31 March 2025

8,268

8,268

Depreciation

At 1 April 2024

353

353

Charge for the year

1,654

1,654

At 31 March 2025

2,007

2,007

Carrying amount

At 31 March 2025

6,261

6,261

At 31 March 2024

3,830

3,830

6

Debtors

Current

2025
£

2024
£

Other debtors

100

100

 

100

100

7

Creditors

Creditors: amounts falling due within one year

 

Probus Medicines Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Note

2025
£

2024
£

Due within one year

 

Trade creditors

 

162

-

Amounts owed to group undertakings and undertakings in which the company has a participating interest

9

5,789

163

Accruals and deferred income

 

1,000

900

Other creditors

 

15,752

14,522

 

22,703

15,585

8

Share capital

Allotted, called up and not fully paid shares

2025

2024

No.

£

No.

£

Ordinary shares of £1 each

100

100

100

100

       

9

Related party transactions

The company's immediate parent is Probus Surgery limited, incorporated in England.